Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with a directed share issue
Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

August 17, 2021 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

 Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.
January 23, 2026

Vinge advises EQT AB on its combination with Coller Capital

 Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.
January 22, 2026

Vinge advises Nordic Re-Finance AB on a Swedish railway financing

Vinge has acted as Swedish legal counsel to Nordic Re-Finance AB, a leading lessor of locomotives for rail freight traffic in Scandinavia, in connection with the execution of a EUR 250m debt package fully underwritten by Natixis CIB.
January 21, 2026